Provided by Tiger Trade Technology Pte. Ltd.

Exelixis

41.26
0.0000
Post-market: 41.260.00000.00%17:51 EDT
Volume:2.10M
Turnover:86.31M
Market Cap:10.72B
PE:14.84
High:41.62
Open:40.94
Low:40.90
Close:41.26
52wk High:49.62
52wk Low:32.38
Shares:259.71M
Float Shares:223.00M
Volume Ratio:0.88
T/O Rate:0.94%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.78
EPS(LYR):2.78
ROE:35.53%
ROA:19.27%
PB:4.96
PE(LYR):14.84

Loading ...

Exelixis Inc. Files Initial Statement of Beneficial Ownership for SVP and General Counsel Brenda Hefti

Reuters
·
Nov 21, 2025

Will Strong Q3 Results and $750M Buyback Shift Exelixis' (EXEL) Outlook?

Simply Wall St.
·
Nov 15, 2025

RBC Capital Keeps Their Hold Rating on Exelixis (EXEL)

TIPRANKS
·
Nov 14, 2025

A Fresh Look at Exelixis (EXEL) Valuation After Strong Earnings and New $750 Million Buyback

Simply Wall St.
·
Nov 14, 2025

Exelixis Inc. Director Stelios Papadopoulos Reports Disposal of Common Shares

Reuters
·
Nov 14, 2025

Exelixis EVP Dana Aftab Reports Disposal of Common Shares

Reuters
·
Nov 14, 2025

Exelixis Director Mary C. Beckerle Reports Sale of Common Shares

Reuters
·
Nov 14, 2025

Exelixis Announces Leadership Transition with New General Counsel

TIPRANKS
·
Nov 08, 2025

Exelixis Names Brenda Hefti as New General Counsel

Reuters
·
Nov 08, 2025

Exelixis Inc. to Present at Major Healthcare Investor Conferences

Reuters
·
Nov 07, 2025

Exelixis Is Maintained at Neutral by UBS

Dow Jones
·
Nov 07, 2025

UBS Adjusts Price Target on Exelixis to $40 From $35, Maintains Neutral Rating

MT Newswires Live
·
Nov 06, 2025

Exelixis (EXEL): Earnings Growth Accelerates to 72%, Reinforcing Bullish Market Narratives

Simply Wall St.
·
Nov 06, 2025

Exelixis Is Maintained at Equal-Weight by Barclays

Dow Jones
·
Nov 06, 2025

Exelixis Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Nov 06, 2025

Exelixis price target raised to $49 from $46 at H.C. Wainwright

TIPRANKS
·
Nov 06, 2025

Analysts’ Opinions Are Mixed on These Healthcare Stocks: PROCEPT BioRobotics (PRCT), Day One Biopharmaceuticals (DAWN) and Exelixis (EXEL)

TIPRANKS
·
Nov 06, 2025

Stock Track | Exelixis (EXEL) Soars 5.54% Pre-Market as Multiple Analysts Raise Price Targets

Stock Track
·
Nov 05, 2025

Morgan Stanley Lifts Price Target on Exelixis to $45 From $44, Keeps Overweight Rating

MT Newswires Live
·
Nov 05, 2025

Barclays Keeps Their Hold Rating on Exelixis (EXEL)

TIPRANKS
·
Nov 05, 2025